In June 2024, the Centers for Disease Control and Prevention (CDC) issued guidelines for the use of DoxyPEP—or doxycycline post-exposure prophylaxis—as a strategy to help prevent bacterial sexually transmitted infections (STIs) among some populations, like men who have sex with men.
DoxyPEP is an effective tool to significantly reduce bacterial STIs, specifically syphilis, chlamydia, and gonorrhea, by 50-80%. However, more research is needed before more populations, like women, can have access to DoxyPEP.